Mizuho Initiates Coverage On Maze Therapeutics with Outperform Rating, Announces Price Target of $97
Maze Therapeutics, Inc. -4.27%
Maze Therapeutics, Inc. MAZE | 26.69 | -4.27% |
Mizuho analyst Salim Syed initiates coverage on Maze Therapeutics (NASDAQ:
MAZE) with a Outperform rating and announces Price Target of $97.
